Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
HZNP Horizon Therapeutics Public Limited Company weekly Stock Chart
HZNP [NASD]
Horizon Therapeutics Public Limited Company
Healthcare | Drug Manufacturers - General | Ireland
statements
Index- P/E20.19 EPS (ttm)2.84 Insider Own0.80% Shs Outstand190.07M Perf Week3.60%
Market Cap11.07B Forward P/E21.22 EPS next Y2.70 Insider Trans-31.08% Shs Float188.15M Perf Month17.77%
Income592.30M PEG1.12 EPS next Q0.28 Inst Own92.10% Short Float4.91% Perf Quarter84.43%
Sales1.38B P/S8.04 EPS this Y736.30% Inst Trans0.17% Short Ratio3.49 Perf Half Y57.75%
Book/sh11.51 P/B4.97 EPS next Y49.25% ROA14.60% Target Price53.50 Perf Year143.84%
Cash/sh3.90 P/C14.66 EPS next 5Y18.00% ROE31.80% 52W Range22.84 - 59.21 Perf YTD58.09%
Dividend- P/FCF64.11 EPS past 5Y23.90% ROI18.70% 52W High-5.67% Beta1.22
Dividend %- Quick Ratio2.30 Sales past 5Y34.40% Gross Margin73.00% 52W Low144.53% ATR1.96
Employees1185 Current Ratio2.40 Sales Q/Q26.90% Oper. Margin4.30% RSI (14)59.48 Volatility3.67% 3.66%
OptionableYes Debt/Eq0.00 EPS Q/Q62.40% Profit Margin43.10% Rel Volume0.90 Prev Close57.23
ShortableYes LT Debt/Eq0.62 EarningsMay 06 BMO Payout0.00% Avg Volume2.65M Price55.85
Recom1.70 SMA204.28% SMA5014.20% SMA20053.83% Volume2,391,759 Change-2.41%
Jan-08-20Initiated Goldman Neutral $35
Sep-26-19Initiated BofA/Merrill Buy $34
Sep-12-19Initiated Guggenheim Buy
Aug-14-19Upgrade BMO Capital Markets Market Perform → Outperform $29 → $36
May-01-19Upgrade Citigroup Neutral → Buy $21 → $32
Mar-08-19Upgrade Morgan Stanley Equal-Weight → Overweight $32
Nov-15-18Downgrade Mizuho Buy → Neutral
Jun-27-18Downgrade Citigroup Buy → Neutral
Jan-12-18Upgrade Mizuho Neutral → Buy $12 → $18
Sep-28-17Initiated Goldman Buy $16
Jun-16-17Initiated Cantor Fitzgerald Overweight $13
May-09-17Reiterated Stifel Buy $35 → $20
May-09-17Downgrade Mizuho Buy → Neutral $22 → $10
Feb-28-17Reiterated Mizuho Buy $25 → $22
Dec-16-16Upgrade Mizuho Neutral → Buy $14 → $25
Dec-09-16Downgrade Mizuho Buy → Neutral $30 → $14
Nov-28-16Upgrade Citigroup Neutral → Buy
Nov-08-16Reiterated Mizuho Buy $29 → $30
Oct-31-16Reiterated Mizuho Buy $33 → $29
Sep-13-16Reiterated Mizuho Buy $30 → $33
Jul-13-20 08:30AM  
Horizon Therapeutics plc to Release Second-Quarter 2020 Financial Results and Host Webcast on Aug. 5, 2020
Business Wire
Jul-09-20 08:30AM  
Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for TEPEZZA® (teprotumumab-trbw) Effective Oct. 1, 2020
Business Wire
08:00AM  
HemoShear Therapeutics Achieves Milestone in Exclusive Drug Discovery Collaboration with Horizon Therapeutics in Gout
PR Newswire
Jul-08-20 10:00AM  
Why These 3 Pharma Stocks Are Outplaying 90% Of The Stock Market
Investor's Business Daily
Jul-07-20 04:49PM  
Were Hedge Funds Right About Horizon Therapeutics Public Limited Company (HZNP) ?
Insider Monkey
Jul-01-20 09:00AM  
New Initiative Encourages the Graves Disease Community to FOCUS on Eye Health
Business Wire
Jun-23-20 11:38AM  
These 3 Growth Stocks Could Hold Value
GuruFocus.com
Jun-03-20 08:05AM  
Horizon Therapeutics plc Announces Redemption of All $400 Million of Its Exchangeable Senior Notes
Business Wire
08:00AM  
Data Presented on KRYSTEXXA® (pegloticase injection) Co-Prescribed with an Immunomodulator Adds to Growing Body of Evidence for this Treatment Approach
Business Wire
May-30-20 01:06PM  
Is Horizon Therapeutics (HZNP) A Good Stock To Buy?
Insider Monkey
May-27-20 03:36PM  
Edited Transcript of HZNP earnings conference call or presentation 6-May-20 12:00pm GMT
Thomson Reuters StreetEvents
May-21-20 09:15AM  
Horizon Therapeutics Named Number One Best Workplace in Chicago
Business Wire
08:00AM  
Data on Multiple Immunomodulation Approaches with KRYSTEXXA® (pegloticase injection) to be Presented at the Annual European Congress of Rheumatology (EULAR 2020)
Business Wire
May-19-20 08:00AM  
Horizon Therapeutics to Participate in Upcoming Investor Conferences
Business Wire
May-14-20 09:00AM  
New Data on the Pharmacokinetic Profile of TEPEZZA (teprotumumab-trbw) Reinforce the Labeled Dosing Regimen, Indicating a Positive, Consistent Response to Therapy
Business Wire
May-11-20 12:00PM  
U.S. Physician Survey Illustrates the Devastating Impact of Thyroid Eye Disease on Patient Quality of Life
Business Wire
May-06-20 12:39PM  
Why Horizon Therapeutics Is Soaring Today
Motley Fool +13.96%
10:43AM  
Horizon Therapeutics Breaks Out
Investor's Business Daily Video
07:00AM  
Horizon Therapeutics plc Reports Strong First-Quarter 2020 Financial Results; Increasing TEPEZZA Full-Year 2020 Net Sales Guidance to Greater Than $200 Million Due to Rapid Uptake; Increasing Full-Year 2020 Net Sales Guidance
Business Wire
Apr-27-20 08:10AM  
Horizon Therapeutics plc Announces Availability of PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets in the United States
Business Wire
Apr-15-20 08:00AM  
Horizon Therapeutics plc to Release First-Quarter 2020 Financial Results and Host Webcast on May 6, 2020
Business Wire
Apr-09-20 09:00AM  
Horizon Therapeutics plc Named One of the 2020 Best Workplaces in Health Care and Biopharma by Fortune and Great Place to Work®
Business Wire
Apr-02-20 08:00AM  
Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
Business Wire +5.48%
Mar-31-20 12:00PM  
TEPEZZA (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes
Business Wire
Mar-26-20 04:15PM  
Horizon Therapeutics plc Donates $1.5 Million to COVID-19 Response Efforts in Illinois and Other Impacted U.S. and Global Communities
Business Wire
Mar-22-20 10:13PM  
Should You Buy Horizon Pharma Public Limited Company (HZNP)?
Insider Monkey
Mar-18-20 08:01AM  
Should You Worry About Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) CEO Salary Level?
Simply Wall St. -6.94%
Mar-17-20 02:04PM  
Top Pharmaceutical Stocks for Q2 2020
Investopedia
Mar-03-20 08:00AM  
Horizon Therapeutics plc Launches the Down and Out Kidney Campaign to Call Attention to the Prevalence and Impact of Gout in Chronic Kidney Disease
Business Wire
Feb-28-20 10:00AM  
Horizon and Willis Tower Elevate the Need for Rare Disease Innovation on Rare Disease Day
Business Wire
08:00AM  
Horizon Therapeutics plc Partners with EveryLife Foundation to Establish $1 Million #RAREis Scholarship for Adults with Rare Diseases
Business Wire
Feb-27-20 08:00AM  
Horizon Therapeutics plc Named One of the Best Workplaces in Ireland
Business Wire
03:10AM  
Edited Transcript of HZNP earnings conference call or presentation 26-Feb-20 1:00pm GMT
Thomson Reuters StreetEvents
Feb-26-20 07:00AM  
Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2019 Financial Results; Announces Full-Year 2020 Guidance
Business Wire
Feb-18-20 08:30AM  
Horizon Therapeutics plc to Present at the Cowen and Company 40th Annual Health Care Conference
Business Wire
08:00AM  
Horizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules
Business Wire
Feb-11-20 08:00AM  
Uplifting Athletes Announces Horizon Therapeutics plc as Exclusive Sponsor to Help Tackle Rare Disease at the National Football League (NFL) Scouting Combine
Business Wire
Feb-06-20 10:51AM  
Allergan (AGN) to Report Q4 Earnings: What's in the Cards?
Zacks
Feb-04-20 10:19AM  
What's in Store for Innoviva (INVA) This Earnings Season?
Zacks
08:00AM  
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2019 Financial Results and Host Webcast on Feb. 26, 2020
Business Wire
Jan-28-20 11:10AM  
Horizon Therapeutics Announces Significant Expansion and Relocation of U.S. Operations
Business Wire
Jan-27-20 12:10PM  
Why the Earnings Surprise Streak Could Continue for Horizon Therapeutics (HZNP)
Zacks
Jan-24-20 04:05PM  
Horizon Therapeutics plc Announces Changes in Research and Development Organization
Business Wire
Jan-23-20 11:40AM  
REGN vs. HZNP: Which Stock Is the Better Value Option?
Zacks
Jan-22-20 05:20PM  
The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial (OPTIC) of TEPEZZA (teprotumumab-trbw) for Thyroid Eye Disease
Business Wire
10:03AM  
Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza
Zacks
09:45AM  
Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon
Zacks
Jan-21-20 03:04PM  
FDA Approves TEPEZZATM (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED)
Business Wire
02:59PM  
FDA approves Horizon's drug for thyroid eye disease
Reuters
Jan-18-20 09:08AM  
Are Investors Undervaluing Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) By 37%?
Simply Wall St.
Jan-15-20 05:00AM  
Top Picks 2020- Horizon Therapeutics HZNP and Qorvo QRVO
MoneyShow
Jan-14-20 07:55AM  
The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug
Benzinga
Jan-13-20 08:15AM  
Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers; Provides Update on Several Pipeline Programs
Business Wire
08:05AM  
MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate
Business Wire
Jan-03-20 09:58AM  
Horizon Therapeutics' Stock Up in a Year on Pipeline Progress
Zacks
Jan-02-20 08:34AM  
3 Healthcare Stocks Primed for 2020 Gains
TipRanks
Dec-26-19 10:56AM  
How Did Horizon Pharma Public Limited Company (HZNP) Compare Against Top Hedge Fund Stocks in 2019?
Insider Monkey
Dec-20-19 11:40AM  
ALXN vs. HZNP: Which Stock Should Value Investors Buy Now?
Zacks
Dec-16-19 09:46AM  
Horizon Therapeutics Eye Drug Gets Positive FDA Advisory Vote
Zacks
08:40AM  
Horizon's stock jumps on FDA adcomm support for eye drug
MarketWatch
Dec-13-19 04:01PM  
FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED)
Business Wire
07:11AM  
Horizon Therapeutics halted for FDA advisory committee meeting on treatment for thyroid eye disease
MarketWatch
07:00AM  
Horizon Therapeutics plc Trading Halted Today; FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting to Discuss Teprotumumab for Thyroid Eye Disease
Business Wire
Dec-09-19 08:00AM  
Horizon Therapeutics plc to Present at the 38th Annual J.P. Morgan Healthcare Conference
Business Wire
Dec-06-19 11:31AM  
Why Is Horizon Therapeutics (HZNP) Up 7.5% Since Last Earnings Report?
Zacks
Dec-04-19 11:27AM  
Should We Be Cautious About Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) ROE Of 3.0%?
Simply Wall St.
Dec-03-19 10:04AM  
Here is What Hedge Funds Think About Horizon Pharma Public Limited Company (HZNP)
Insider Monkey
Nov-25-19 09:35AM  
How location, focus and CEO's own rare-disease diagnosis is driving this drug company
American City Business Journals
Nov-24-19 06:29PM  
S&P 500: Winning Streak Ends
TipRanks
Nov-22-19 08:00AM  
Horizon Therapeutics plc Opens New Manufacturing and R&D Facility in South San Francisco
Business Wire
Nov-21-19 08:00AM  
Horizon Therapeutics plc Launches New Online Community Connecting People Living with Thyroid Eye Disease and Urging them to Listen to Your Eyes
Business Wire
Nov-14-19 09:30AM  
FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Workplaces for Parents List
Business Wire
Nov-13-19 04:15PM  
Horizon Therapeutics plc to Participate in Upcoming Investor Conferences
Business Wire
Nov-11-19 02:05PM  
Edited Transcript of HZNP earnings conference call or presentation 6-Nov-19 1:00pm GMT
Thomson Reuters StreetEvents
08:00AM  
Data from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA® (pegloticase injection) Strategy to Optimize Treatment Outcomes
Business Wire
05:57AM  
3 Market-Beating Stocks for Your 2020 Radar
TipRanks
Nov-08-19 10:02AM  
After sons rare disease diagnosis, father finds hope through film festival
American City Business Journals
09:30AM  
The Chicago Tribune Names Horizon Therapeutics plc a 2019 Top Workplace
Business Wire
Nov-07-19 11:05AM  
Horizon Therapeutics' (HZNP) Q3 Earnings Beat Estimates
Zacks
Nov-06-19 08:45AM  
Horizon Therapeutics (HZNP) Q3 Earnings and Revenues Beat Estimates
Zacks
07:00AM  
Horizon Therapeutics plc Reports Strong Third-Quarter 2019 Results
Business Wire
Nov-05-19 08:00AM  
Horizon Therapeutics plc Brings Gout-Kidney Link into Focus during American Society of Nephrology (ASN) Kidney Week 2019
Business Wire
Nov-04-19 08:30AM  
Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting
Business Wire
08:00AM  
New Evidence on the Burden of Gout to be Featured in Data Presentations at Upcoming ACR Annual Meeting
Business Wire
Oct-31-19 10:00AM  
Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life
Business Wire
Oct-30-19 10:33AM  
Analysts Estimate Horizon Therapeutics (HZNP) to Report a Decline in Earnings: What to Look Out for
Zacks
Oct-24-19 11:15AM  
Horizon Therapeutics plc Named One of the Most Innovative Companies by Crains Chicago Business
Business Wire
09:30AM  
HZNP or BMRN: Which Is the Better Value Stock Right Now?
Zacks
08:00AM  
New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meeting
Business Wire
Oct-17-19 04:48PM  
Did Hedge Funds Drop The Ball On Horizon Therapeutics Public Limited Company (HZNP) ?
Insider Monkey
09:00AM  
FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Small & Medium Workplaces List for Fourth Consecutive Year
Business Wire
08:41AM  
Is Horizon Therapeutics's (NASDAQ:HZNP) 128% Share Price Increase Well Justified?
Simply Wall St.
08:00AM  
Horizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant
Business Wire
Oct-16-19 03:23PM  
Four stocks that are nearing key breakouts
MarketWatch
11:51AM  
4 Stocks Nearing Key Breakouts
Benzinga
Oct-11-19 12:30PM  
New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease
Business Wire
Oct-10-19 09:00AM  
For World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put Vision First
Business Wire
Oct-09-19 08:00AM  
Horizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019
Business Wire
Oct-08-19 08:00AM  
New Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium
Business Wire
Oct-03-19 08:00AM  
Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
Business Wire
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company's primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kent JeffSee remarksJul 07Option Exercise5.6838,000215,98098,993Jul 07 06:57 PM
MOZE BARRYEVP, Chief Admin. OfficerJul 07Option Exercise13.1735,076461,918178,209Jul 07 06:50 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerJul 06Sale57.509,100523,250278,797Jul 07 06:49 PM
MOZE BARRYEVP, Chief Admin. OfficerJul 01Sale54.6423,1581,265,441143,133Jul 02 04:46 PM
GREY MICHAEL GDirectorJun 25Option Exercise3.951,7556,9321,755Jun 26 05:00 PM
GREY MICHAEL GDirectorJun 25Sale55.001,75596,5250Jun 26 05:00 PM
Kent JeffSee remarksJun 10Sale48.052,785133,81960,993Jun 12 06:00 PM
Kent JeffSee remarksJun 01Sale49.9457,2152,857,17960,994Jun 02 06:18 PM
Karnani VikramEVP, Chief Commercial OfficerJun 01Sale50.232,369118,99542,169Jun 02 06:17 PM
Beeler Brian KEVP, General CounselJun 01Sale50.232,370119,04535,885Jun 02 06:16 PM
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOMay 26Sale49.8521,9181,092,61234,834May 27 05:00 PM
GREY MICHAEL GDirectorMay 22Option Exercise7.8410,53082,55510,530May 26 05:00 PM
GREY MICHAEL GDirectorMay 22Sale48.7710,530513,5050May 26 05:00 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerMay 11Option Exercise4.9633,479166,05647,445May 12 04:12 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerMay 11Sale45.0033,4791,506,55513,966May 12 04:12 PM
McHugh Miles WSr VP & Princ. Acctg OfficerMay 11Sale44.2249,1142,171,58530,816May 12 04:11 PM
McHugh Miles WSr VP & Princ. Acctg OfficerMay 08Sale43.5145,3661,973,71179,930May 12 04:11 PM
DesJardin Michael A.EVP, Technical OperationsMay 07Option Exercise14.9323,159345,76464,359May 07 04:29 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffMay 06Option Exercise14.0559,794840,10695,183May 07 04:31 PM
DesJardin Michael A.EVP, Technical OperationsMay 06Sale41.5917,959747,00441,200May 07 04:29 PM
Beeler Brian KEVP, General CounselMay 06Sale40.8048,0001,958,51537,206May 07 04:32 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffMay 06Sale41.1959,7942,462,91535,389May 07 04:31 PM
McHugh Miles WSr VP & Princ. Acctg OfficerMay 06Sale41.193,545146,019129,095May 07 04:30 PM
McHugh Miles WSr VP & Princ. Acctg OfficerMay 05Sale37.005,007185,259132,640May 07 04:30 PM
DesJardin Michael A.EVP, Technical OperationsMay 05Sale38.008,980341,24059,159May 07 04:29 PM
Hoelscher Paul W.EVP, CFOMay 05Sale38.00104,9943,989,772132,501May 07 04:27 PM
Beeler Brian KEVP, General CounselApr 29Sale35.0215,880556,11885,206Apr 30 05:50 PM
Karnani VikramEVP, Chief Commercial OfficerApr 29Sale35.0015,683548,90543,489Apr 30 05:49 PM
Karnani VikramEVP, Chief Commercial OfficerApr 28Sale35.0130,0631,052,50659,172Apr 30 05:49 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffApr 20Sale34.1319,886678,68535,389Apr 21 05:00 PM
Beeler Brian KEVP, General CounselApr 16Sale32.519,000292,615101,086Apr 17 04:23 PM
Beeler Brian KEVP, General CounselApr 07Sale32.502979,653110,086Apr 08 04:46 PM
Beeler Brian KEVP, General CounselApr 06Sale32.502,37077,025110,383Apr 08 04:46 PM
MOZE BARRYEVP, Chief Admin. OfficerMar 30Option Exercise12.942,10627,252168,397Mar 31 05:01 PM
MOZE BARRYEVP, Chief Admin. OfficerMar 30Sale28.182,10659,347166,291Mar 31 05:01 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerMar 11Option Exercise12.945,28768,41413,966Mar 13 04:15 PM
McHugh Miles WSr VP & Princ. Acctg OfficerFeb 27Sale34.341,00034,3420Feb 28 05:00 PM
Walbert Timothy PChairman, President and CEOFeb 21Sale35.2393,8643,306,829847,743Feb 21 08:07 PM
Walbert Timothy PChairman, President and CEOFeb 01Option Exercise0.009,086011,818Feb 04 04:14 PM
Kent JeffSee remarksJan 07Sale36.503,545129,393111,667Jan 07 06:30 PM
Karnani VikramEVP, Chief Commercial OfficerJan 06Sale35.629,297331,15978,146Jan 07 06:23 PM
Walbert Timothy PChairman, President and CEOJan 06Sale35.5784,8863,019,395903,309Jan 07 06:18 PM
Beeler Brian KEVP, General CounselDec 18Sale35.006,716235,06077,917Dec 20 04:46 PM
Beeler Brian KEVP, General CounselNov 25Sale32.519,969324,09384,633Nov 27 04:18 PM
McHugh Miles WSr VP & Princ. Acctg OfficerNov 14Option Exercise22.144,51699,984127,096Nov 15 04:19 PM
Beeler Brian KEVP, General CounselNov 05Sale30.0212,475374,46294,602Nov 07 04:38 PM
Walbert Timothy PChairman, President and CEOOct 15Option Exercise5.82311,8691,814,8791,097,165Oct 17 04:41 PM
Hoelscher Paul W.EVP, CFOOct 15Sale28.0120,000560,100139,310Oct 17 04:42 PM
Walbert Timothy PChairman, President and CEOOct 15Sale28.02320,1748,970,283776,991Oct 17 04:41 PM
Shannon James SamuelDirectorSep 13Option Exercise12.199,500115,8059,500Sep 13 06:52 PM
Shannon James SamuelDirectorSep 13Sale26.199,500248,8050Sep 13 06:52 PM
Shannon James SamuelDirectorSep 12Option Exercise12.1915,500188,94515,500Sep 13 06:52 PM
Shannon James SamuelDirectorSep 12Sale26.5915,500412,1310Sep 13 06:52 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffSep 12Sale26.7017,838476,27519,886Sep 13 06:51 PM
Hoelscher Paul W.EVP, CFOAug 30Sale28.001,35938,052159,310Sep 04 05:41 PM
Walbert Timothy PChairman, President and CEOAug 30Sale28.002,50070,000785,296Sep 04 05:34 PM
Hoelscher Paul W.EVP, CFOAug 22Option Exercise16.9029,576499,942160,669Aug 23 04:58 PM
Walbert Timothy PChairman, President and CEOAug 22Sale28.001,98455,552787,796Aug 23 04:57 PM
Hoelscher Paul W.EVP, CFOAug 21Sale28.0070,9031,985,426131,093Aug 23 04:58 PM
Walbert Timothy PChairman, President and CEOAug 21Sale28.0056,8361,591,518789,780Aug 23 04:57 PM
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOAug 08Sale26.5820,609547,83028,382Aug 12 04:58 PM
Kent JeffSee remarksAug 05Sale23.8411,140265,540107,115Aug 05 04:59 PM
open in yahoo | open in reuters | open in google